Introduction
Drug-drug interactions (DDIs) represent a significant clinical concern, particularly when one medication alters the metabolic clearance of another. This study, published in the Japanese Journal of Pharmacology, examines the interaction potential of 480156-S, a propionic acid derivative nonsteroidal anti-inflammatory drug (NSAID).
Previous clinical observations suggested that 480156-S might inhibit oxidative metabolism in the liver. The researchers aimed to characterize this inhibition, determine its specificity across Cytochrome P-450 (P-450) isozymes, and evaluate its impact on the pharmacological duration of co-administered drugs like diazepam and pentobarbital.
Methods
The study utilized male and female Wistar and SD rats. Hepatic drug-metabolizing activity was assessed by measuring 7-alkoxycoumarin O-dealkylase activities (O-demethylase, O-deethylase, and O-depropylase) in liver homogenates.
Pharmacological interactions were evaluated using two "probe" drugs:
- Diazepam: Muscle relaxation was measured via an inclined screen test, alongside anti-convulsant assays.
- Pentobarbital: Anesthesia duration was measured by "sleeping time."
The effects of 480156-S (10–50 mg/kg) were compared with ibuprofen and the known P-450 inhibitor cimetidine.
Key Results
Selective and Cumulative Enzyme Inhibition
A single dose of 480156-S did not significantly affect P-450 activity. However, repeated administration (3–7 days) led to a dose-dependent suppression of specific activities. Notably, the inhibition was highly selective: O-demethylase activity was significantly reduced, while O-depropylase activity remained largely unaffected. This suggests that 480156-S targets specific P-450 isozymes rather than acting as a broad-spectrum inhibitor.
Prolongation of Diazepam Effects
The selective inhibition of liver enzymes translated into significant pharmacological changes. Pre-treatment with 480156-S markedly prolonged the muscle-relaxant and anti-convulsant effects of diazepam.
As shown in Figure 2, the recovery of muscle tone (measured by the degree of inclination) was significantly delayed in rats treated with 480156-S (Panel A) compared to controls. While ibuprofen (Panel B) showed a similar trend, its effect was less pronounced. Cimetidine (Panel C) also caused significant prolongation, but its inhibitory effect was transient, recovering within 24 hours. In contrast, 480156-S-induced inhibition persisted for up to 48 hours post-dose.
Isozyme Specificity: Diazepam vs. Pentobarbital
A critical finding was the lack of interaction between 480156-S and pentobarbital. While cimetidine nearly tripled pentobarbital sleeping time, 480156-S had no effect. This confirms that 480156-S selectively inhibits the isozymes responsible for diazepam metabolism (and its active metabolites like nordiazepam) but does not interfere with the pathways processing pentobarbital.
Conclusion
The NSAID 480156-S acts as a selective, cumulative inhibitor of specific hepatic Cytochrome P-450 isozymes in rats. This inhibition leads to a clinically relevant prolongation of diazepam's pharmacological action. The delay in onset of inhibition (requiring repeated dosing) and its persistence suggest that either the drug itself or a metabolite accumulates to reach inhibitory concentrations. These findings highlight the importance of considering isozyme-specific DDIs during the development and clinical use of new NSAIDs.
Reference: Matsubara, T., et al. (1988). Effect of the nonsteroidal anti-inflammatory drug 480156-S on hepatic drug-metabolizing activity and pharmacological action of diazepam and pentobarbital in rats. Folia pharmacol. japon. 92, 201-213.
Summary updated